
Phage Display Peptide Probes For Imaging Early Response To Cancer TherapyAward last edited on: 1/30/12
Sponsored Program
SBIRAwarding Agency
NIH : NCITotal Award Amount
$236,000Award Phase
1Solicitation Topic Code
-----Principal Investigator
Jenny C WuCompany Information
Acaduceus Pharmaceutics Inc
11171 Bubb Road
Cupertino, CA 95014
Cupertino, CA 95014
(408) 306-5635 |
jennywu@acaduceuspharma.com |
www.acaduceuspharma.com |
Location: Single
Congr. District: 18
County: Santa Clara
Congr. District: 18
County: Santa Clara
Phase I
Contract Number: 1R43CA150286-01A1Start Date: 9/5/11 Completed: 8/31/12
Phase I year
2011Phase I Amount
$236,000Public Health Relevance:
We will develop the clinically translatable novel molecular imaging probes for monitoring tumor early response and efficacy to anti-angiogenic treatment regimens. Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. We anticipate that the new tracers will provide early evaluation of cancer response to a therapeutic regimen that can help accelerate the drug development, adjust the efficacious treatment scheme, reduce the healthcare cost, eventually leading to personalized cancer therapy, treatment monitoring, and dose optimization.
Thesaurus Terms:
Affinity;Angiogenesis Antagonists;Angiogenesis Blockers;Angiogenesis Inhibitors;Angiogenetic Antagonists;Angiogenetic Inhibitors;Angiogenic Antagonists;Angiogenic Inhibitors;Angiostatic Agents;Anti-Angiogenesis;Anti-Angiogenetic Agents;Anti-Angiogenic Agents;Anti-Angiogenic Drugs;Antiangiogenesis;Antiangiogenesis Agents;Antiangiogenic Agents;Avastin;Binding;Binding (Molecular Function);Cancer Patient;Cancer Treatment;Cancers;Clinical;Clinical Evaluation;Clinical Oncology;Clinical Protocols;Clinical Testing;Computer Models;Computer Simulation;Computer Based Simulation;Computerized Models;Development;Disease;Disorder;Docking;Dose;Drug Delivery;Drug Delivery Systems;Drug Kinetics;Drug Targeting;Drugs;Evaluation;Expenditure;Far-Western Blotting;Goals;Health Care Costs;Health Costs;Healthcare Costs;Image;Imaging Procedures;Imaging Technics;Imaging Techniques;Industry;Loinc Axis 2 Property;Label;Malignant Neoplasm Therapy;Malignant Neoplasm Treatment;Malignant Neoplasms;Malignant Tumor;Mathematical Model Simulation;Mathematical Models And Simulations;Measures;Medication;Metabolic;Modeling;Molecular Interaction;Molecular Target;Monitor;Neovascularization Inhibitors;Oncology Cancer;Pet;Pet Scan;Pet Imaging;Petscan;Pett;Patients;Peptide Phage Display Library;Peptides;Phage Display;Pharmaceutic Preparations;Pharmaceutical Preparations;Pharmaceutics;Pharmacokinetics;Pharmacy (Field);Phase;Phase I Study;Positron Emission Tomography Medical Imaging;Positron Emission Tomography Scan;Positron-Emission Tomography;Pre-Clinical Model;Preclinical Models;Preparation;Property;Protein Binding;Proteins;Proteomics;Rad.-Pet;Radiation Therapy;Radiolabeled;Radiotherapeutics;Radiotherapy;Regimen;Relapse;Reporting;Sbir;Sbirs (R43/44);Sales;Schedule;Scheme;Sensitivity And Specificity;Small Business Innovation Research;Small Business Innovation Research Grant;Solid;Technology;Testing;Therapeutic;Toxic Effect;Toxicities;Tracer;Translations;Treatment Efficacy;Treatment Period;Treatment Protocols;Treatment Regimen;Treatment Schedule;Tumor Angiogenesis;Tumor Volume;West-Western Blotting;Angiogenesis;Antiangiogenesis Therapy;Antiangiogenic;Anticancer Research;Anticancer Therapy;Base;Biomarker;Cancer Research;Cancer Therapy;Cellular Targeting;Clinical Applicability;Clinical Application;Clinical Relevance;Clinical Test;Clinically Relevant;Computational Modeling;Computational Models;Computational Simulation;Computer Based Models;Computerized Modeling;Computerized Simulation;Cost;Developmental;Disease/Disorder;Drug Development;Drug Discovery;Drug/Agent;Experiment;Experimental Research;Experimental Study;Gene Product;Imaging;Imaging Probe;Improved;In Silico;In Vivo;Innovate;Innovation;Innovative;Insight;Intervention Efficacy;Laser Capture Microdissection;Malignancy;Molecular Imaging;Multimodality;Neoplasm/Cancer;New Approaches;Novel;Novel Approaches;Novel Strategies;Novel Strategy;Oncology;Patient Population;Phase 1 Study;Phase 2 Study;Phase Ii Study;Pre-Clinical Research;Preclinical Research;Preclinical Toxicity;Product Development;Programs;Radiolabel;Radiotracer;Research Clinical Testing;Research Study;Response;Safety Study;Success;Therapeutic Efficacy;Therapeutically Effective;Therapy Efficacy;Treatment Days;Treatment Duration;Tumor;Uptake;Virtual Simulation
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00